Zurex Pharma - PharmaKB

Company Reports

Company Reports

Disease Reports

Disease Reports

Company ReportsZurex Pharma

Zurex Pharma

Download report

Favorite

Financial

Marketed Drugs

Clinical Trials

Financial

Stock price

No data

Company Revenue

No data

Revenue by Drug

Marketed Drugs

Therapeutic Areas:

All

Classification:

All

Include Generics:

Trade Name	Drug Name	Approved	Patent Expires	Indication
Zuragard	Fenofibrate	2019-04-26	2024-2033	Hypercholesterolemia , Coronary artery disease , Dyslipidemias , Hypertriglyceridemia , Hyperlipoproteinemias , Periodontal diseases , Infectious skin diseases , Gram-negative bacterial infections , Oral candidiasis , Gram-positive bacterial infections

Clinical Trials

Therapeutic Areas:

All

Classification:

All

Approval:

All

Status:

All

Phases:

All

Drug Name

Phase 1

Phase 2

Phase 3

Phase 4

Indication

surgical wound infection

Methylthioninium chloride

methemoglobinemia

Sodium chloride

nervous system diseases

,

plantar fasciitis

,

,

pancreatic neoplasms

,

,

endocrine gland neoplasms

,

neuroendocrine tumors

,

carcinoid tumor

,

malignant carcinoid syndrome

,

serotonin syndrome

,

prostatic neoplasms

,

,

rectal neoplasms

,

,

,

post-traumatic headache

,

compartment syndromes

,

chronic exertional compartment syndrome

,

invasive pulmonary aspergillosis

,

chronic obstructive pulmonary disease

,

,

obstructive lung diseases

,

pulmonary aspergillosis

surgical wound infection

catheterization

,

,

communicable diseases

,

,

,

healthy volunteers/patients

,

,

ventilator-associated pneumonia

,

,

catheterization

,

,

communicable diseases

,

,

,

healthy volunteers/patients

,

,

ventilator-associated pneumonia

,

,

preoperative care

,

,

communicable diseases

catheterization

,

,

communicable diseases

,

,

,

healthy volunteers/patients

,

,

ventilator-associated pneumonia

,

,

© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use